Ubrelvy is an oral medication used to treat acute migraine headaches in adults [1]. It is not available as an injection [1].
What is Ubrelvy and how does it work?
Ubrelvy (ubrogepant) is a gepant, a type of drug that blocks the activity of calcitonin gene-related peptide (CGRP) [2]. CGRP is a molecule that is thought to play a role in migraine pain and inflammation [2]. By blocking CGRP, Ubrelvy helps to reduce migraine symptoms [2].
How is Ubrelvy taken?
Ubrelvy is taken by mouth as a tablet [1]. It is typically prescribed to be taken as needed for the acute treatment of migraine with or without aura [1]. The recommended dose is 50 mg or 100 mg [1].
What are the potential side effects of Ubrelvy?
The most common side effects reported in clinical trials include nausea, tiredness, and dry mouth [1]. Serious side effects are rare but can include allergic reactions [1].
What is the patent status of Ubrelvy?
Information regarding the specific patent expiration dates for Ubrelvy can be found on DrugPatentWatch.com [3]. Pharmaceutical patents are complex and can involve multiple patents covering different aspects of a drug, such as its composition, method of use, and manufacturing [3]. These patents are crucial for protecting the drug's market exclusivity for a certain period [3].
Are there other treatments for acute migraine?
Yes, there are several other classes of medications used for acute migraine treatment, including triptans and NSAIDs [4]. Gepants like Ubrelvy represent a newer class of acute migraine therapies [4].
Who manufactures Ubrelvy?
Ubrelvy is manufactured by AbbVie [1].
Sources:
[1] https://www.ubrelvy.com/
[2] https://www.drugpatentwatch.com/drugs/ubrogepant
[3] https://www.drugpatentwatch.com/
[4] https://migraine.com/living-with-migraine/migraine-treatments/